Sep 13 2024 21 mins 3
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are one of the established treatments used to slow the progression of CKD and improve outcomes. Could perhaps the glucagon-like peptide 1 (GLP-1) receptor agonists provide similar, additive, or different benefits in patients with CKD?
Guest Author: John Swegle, PharmD, BCPS, BCACP
Music by Good Talk
